Literature DB >> 22244823

PGE(2) receptor (EP(4)) agonists: potent dilators of human bronchi and future asthma therapy?

C Benyahia1, I Gomez, L Kanyinda, K Boukais, C Danel, G Leséche, D Longrois, X Norel.   

Abstract

BACKGROUND: Asthma and chronic obstructive pulmonary disease are characterized by inappropriate constriction of the airway smooth muscle. In this context, the physiological response of the human airways to selective relaxant agonists like PGE(2) is highly relevant. The aim of this study was thus to characterize the PGE(2) receptor subtypes (EP(2) or EP(4)) involved in the relaxation of human bronchial preparations.
METHODS: Human bronchial preparations cut as rings were mounted in organ baths for isometric recording of tension and a pharmacological study was performed using selective EP(2) or EP(4) ligands.
RESULTS: In the presence of a thromboxane TP receptor antagonist and indomethacin, PGE(2) induced the relaxation of human bronchi (E(max) = 86 ± 04% of papaverine response; pEC(50) value = 7.06 ± 0.13; n = 6). This bronchodilation was significantly blocked by a selective EP(4) receptor antagonist (GW627368X, 1 and 10 μmol/L) with a pK(B) value of 6.38 ± 0.19 (n = 5). In addition, the selective EP(4) receptor agonists (ONO-AE1-329; L-902688), but not the selective EP(2) receptor agonist (ONO-AE1-259), induced potent relaxation of bronchial preparations pre-contracted with histamine or anti-IgE.
CONCLUSION: PGE(2) and EP(4) agonists induced potent relaxations of human bronchial preparations via EP(4) receptor. These observations suggest that EP(4) receptor agonists could constitute therapeutic agents to treat the increased airway resistance in asthma. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22244823     DOI: 10.1016/j.pupt.2011.12.012

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  23 in total

Review 1.  Emerging concepts in smooth muscle contributions to airway structure and function: implications for health and disease.

Authors:  Y S Prakash
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-10-14       Impact factor: 5.464

2.  The anti-inflammatory effects of PGE2 on human lung macrophages are mediated by the EP4 receptor.

Authors:  Sharonjit K Gill; Yiwen Yao; Linda J Kay; Martin A Bewley; Helen M Marriott; Peter T Peachell
Journal:  Br J Pharmacol       Date:  2016-09-06       Impact factor: 8.739

3.  Bronchodilation induced by PGE2 is impaired in Group III pulmonary hypertension.

Authors:  Gulsev Ozen; Chabha Benyahia; Salma Mani; Kamel Boukais; Adam M Silverstein; Richard Bayles; Andrew C Nelsen; Yves Castier; Claire Danel; Hervé Mal; Lucie H Clapp; Dan Longrois; Xavier Norel
Journal:  Br J Pharmacol       Date:  2019-10-31       Impact factor: 8.739

4.  Activation of EP4 receptors prevents endotoxin-induced neutrophil infiltration into the airways and enhances microvascular barrier function.

Authors:  V Konya; J Maric; K Jandl; P Luschnig; I Aringer; I Lanz; W Platzer; A Theiler; T Bärnthaler; R Frei; G Marsche; L M Marsh; A Olschewski; I T Lippe; A Heinemann; R Schuligoi
Journal:  Br J Pharmacol       Date:  2015-07-31       Impact factor: 8.739

5.  The role of prostaglandin and E series prostaglandin receptor type 4 receptors in the development of bladder overactivity in a rat model of chemically induced prostatic inflammation.

Authors:  Shinsuke Mizoguchi; Amanda S Wolf-Johnson; Jianshu Ni; Kenichi Mori; Takahisa Suzuki; Eiichiro Takaoka; Hiromitsu Mimata; Donald B DeFranco; Zhou Wang; Lori A Birder; Naoki Yoshimura
Journal:  BJU Int       Date:  2019-06-26       Impact factor: 5.588

6.  PGE2 maintains the tone of the guinea pig trachea through a balance between activation of contractile EP1 receptors and relaxant EP2 receptors.

Authors:  J Säfholm; S-E Dahlén; I Delin; K Maxey; K Stark; L-O Cardell; M Adner
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

Review 7.  cAMP regulation of airway smooth muscle function.

Authors:  Charlotte K Billington; Oluwaseun O Ojo; Raymond B Penn; Satoru Ito
Journal:  Pulm Pharmacol Ther       Date:  2012-05-24       Impact factor: 3.410

8.  Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.

Authors:  Katherine N Cahill; Jillian C Bensko; Joshua A Boyce; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2014-09-11       Impact factor: 10.793

9.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

Review 10.  Lipid mediators and allergic diseases.

Authors:  Laura B Fanning; Joshua A Boyce
Journal:  Ann Allergy Asthma Immunol       Date:  2013-07-21       Impact factor: 6.347

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.